Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Illustration: Annelise Capossela/Axios

The U.S. supply of coronavirus vaccines is expected to significantly expand over the next few months, with more than enough doses available to vaccinate all U.S. adults before the end of July, Bloomberg reports.

Why it matters: If manufacturing goes according to plan, the intense competition for shots will end relatively soon, and attention will turn instead to increasing vaccine uptake.

By the numbers: The U.S. is currently administering 1.6 million doses a day, and has a supply of 10 to 15 million doses a week.

  • But the number of shots available weekly will increase steadily through the summer, per drugmakers' public statements and supply deals. Eventually, enough vaccine should be available to administer 4.5 million doses a day.
  • Pfizer and Moderna have said they'll deliver more than 500 million additional doses by the end of July. Each person requires two doses.
  • Johnson & Johnson is expected to deliver 100 million doses of its vaccine, which requires only one shot, by the end of June.

What they're saying: Jeff Zients, the White House coronavirus response coordinator, said earlier this week that the federal government hopes to have enough vaccine supply to cover 300 million Americans by the end of July.

  • According to Bloomberg's analysis, that's likely an underestimate of how many shots will be available and when.

Yes, but: Having vaccines available is not the equivalent of putting shots in arms, as we learned during the initial rollout.

  • Administering several million vaccine doses daily will be a logistical feat even if every American wanted one — which they don't.
  • That means America's vaccine problem will quickly shift from supply to demand.

Go deeper

Dave Lawler, author of World
Feb 19, 2021 - World

U.S. commits $4 billion to COVAX vaccine initiative

Biden. Photo: Kevin Dietsch/UPI/Bloomberg via Getty

The U.S. is committing $2 billion for the global COVAX vaccine initiative within days (using funds already allocated by Congress), plus an additional $2 billion over the next two years, the White House announced ahead of Friday's virtual G7 summit.

Why it matters: Senior administration officials told reporters Thursday evening that they'll use those commitments to "call on G7 partners Friday both to make good on the pledges that are already out there" and to make further investments in global vaccine manufacturing and distribution.

Feb 18, 2021 - Health

Fauci: Some vaccine shipments slowed "to a grinding halt" due to historic winter storm

Coronavirus vaccine shipments have slowed "to a grinding halt" in some areas affected by a devastating winter storm and freezing temperatures, Anthony Fauci, President Biden's chief medical adviser, told MSNBC on Thursday.

Driving the news: A winter storm is still tracking along the Southeast coast, leaving heavy snow and ice along the mid-Atlantic, the National Weather Service said in an early Thursday morning update. Texas has been hit the hardest by the storm, with just under 500,000 people still without power after several days.

Updated 2 hours ago - Politics & Policy

Coronavirus dashboard

Illustration: Annelise Capossela/Axios

  1. Health: Biden: It's "not the time to relax" COVID mitigation efforts — Tracking coronavirus variants through sewage.
  2. Vaccine: FDA advisory panel endorses J&J COVID vaccine for emergency use — About 20% of U.S. adults have received first vaccine dose, White House says — New data reignites the debate over coronavirus vaccine strategy.
  3. Economy: What's really going on with the labor market.
  4. Local: All adult Minnesotans will likely be eligible for COVID-19 vaccine by summer — Another wealthy Florida community receives special access to COVID-19 vaccine.
  5. Sports: Poll weighs impact of athlete vaccination.
  6. World: Brazil's capital enters 24-hour lockdown as coronavirus cases surge.